Contents

Search


bronchopulmonary dysplasia

chronic lung disease of babies Pathology: - environmental injury (hypothesis) Clinical manifestations: 1) develops most commonly in the first 4 weeks after birth 2) mostly occurs in babies who are born more than 4 weeks before their due dates 3) sometimes the babies are full term 4) babies have trouble breathing Management: 1) supplmental oxygen 2) mechanical ventilation may be necessary 3) high-dose dexamethasone (0.5 mg/kg daily) to prevent or treat bronchopulmonary dysplasia in preterm infants of no benefit & may be harmful [1] - inhaled budesonide for prevention in preterm infants - does not prevent neurodevelopmental disability [3] - increases mortality [3] 4) enteral supplementation with docosahexaenoic acid does not improve respiratory outcomes (bronchopulmonary dysplasia) for extremely premature infants [2] 5) prognosis a) most babies live b) in severe cases, a baby may die

General

developmental disorder lung disease

References

  1. Choosing Wisely American Academy of Pediatrics Ten Things Physicians and Patients Should Question. http://www.choosingwisely.org/doctor-patient-lists/american-academy-of-pediatrics/
  2. Collins CT et al. Docosahexaenoic acid and bronchopulmonary dysplasia in preterm infants. N Engl J Med 2017 Mar 30; 376:1245 PMID: 28355511 http://www.nejm.org/doi/10.1056/NEJMoa1611942
  3. Bassler D, Shinwell ES, Hallman M et al Long-Term Effects of Inhaled Budesonide for Bronchopulmonary Dysplasia. N Engl J Med 2018; 378:148-157. January 11, 2018 PMID: 29320647 http://www.nejm.org/doi/full/10.1056/NEJMoa1708831
  4. What Is Bronchopulmonary Dysplasia ? http://www.nhlbi.nih.gov/health/dci/Diseases/Bpd/Bpd_WhatIs.html